In silico evaluation of the resistance of the T790M variant of epidermal growth factor receptor kinase to cancer drug Erlotinib.

about

In silico evaluation of the resistance of the T790M variant of epidermal growth factor receptor kinase to cancer drug Erlotinib.

Item

http://www.wikidata.org/entity/Q47355906

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

In silico evaluation of the re ...... nase to cancer drug Erlotinib.

@en

In silico evaluation of the re ...... nase to cancer drug Erlotinib.

@nl

type

Item

label

In silico evaluation of the re ...... nase to cancer drug Erlotinib.

@en

In silico evaluation of the re ...... nase to cancer drug Erlotinib.

@nl

prefLabel

In silico evaluation of the re ...... nase to cancer drug Erlotinib.

@en

In silico evaluation of the re ...... nase to cancer drug Erlotinib.

@nl

P1476

In silico evaluation of the re ...... inase to cancer drug Erlotinib

@en

P2093

Ratna Chandra

http://www.w3.org/2001/XMLSchema#string

Shashank Singh

http://www.w3.org/2001/XMLSchema#string

Vijeshwar Verma

http://www.w3.org/2001/XMLSchema#string

P2860

Oncogenic mutations counteract intrinsic disorder in the EGFR kinase and promote receptor dimerization

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

Comparison of simple potential functions for simulating liquid water

Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor

Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity

Activation of tyrosine kinases by mutation of the gatekeeper threonine

Structural Basis for the Regulation of Protein Kinase A by Activation Loop Phosphorylation

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

P304

4209-4219

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/07391102.2017.1411293

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Vladimir Uversky

Inderpal Singh

P577

2017-12-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29183267

http://www.w3.org/2001/XMLSchema#string